Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of care agent Clear all
Completed Phase 4 Interventional Results available

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

NCT04502095
View directory record Official record
Conditions
Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
Interventions
Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932893
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PF-02341066, Pemetrexed, Docetaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
119
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users

NCT01614106
View directory record Official record
Conditions
HIV, AIDS, Substance Abuse
Interventions
Retention Clinic
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
2
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Phase 2 Interventional

Safety and Activity of F14 for Management of Pain Following Total Knee Replacement

NCT03541655
View directory record Official record
Conditions
Total Knee Replacement, Postoperative Pain
Interventions
Bupivacaine HCl, F14 (celecoxib)
Drug
Lead sponsor
Arthritis Innovation Corporation
Industry
Eligibility
45 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Denver, Colorado • Dayton, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 10, 2026, 1:07 PM EDT
Terminated Phase 4 Interventional Results available

Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

NCT00596947
View directory record Official record
Conditions
Transplants and Implants
Interventions
Prednisone, rabbit antithymocyte globulin, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
19 Years to 74 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 10, 2026, 1:07 PM EDT
Terminated Not applicable Interventional

Study of Probable Benefit of the Neuro-Spinal Scaffold™ in Subjects With Complete Thoracic AIS A Spinal Cord Injury as Compared to Standard of Care

NCT03762655
View directory record Official record
Conditions
Injury, Spinal Cord
Interventions
Neuro-Spinal Scaffold
Device
Lead sponsor
InVivo Therapeutics
Industry
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Sacramento, California • San Diego, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)

NCT03354143
View directory record Official record
Conditions
Hypertension
Interventions
Standard Care, Intensive Treatment
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

NCT03426891
View directory record Official record
Conditions
Glioblastoma, Brain Tumor, GBM
Interventions
Pembrolizumab, Vorinostat, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 10, 2026, 1:07 PM EDT
Terminated Phase 3 Interventional Results available

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 10, 2026, 1:07 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

NCT07811297
View directory record Official record
Conditions
Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
Interventions
AL58805, AL3818, Temozolomide (TMZ), CCNU
Drug
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

NCT01013649
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
Interventions
3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine, Chemotherapy, Computed Tomography, Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Quality-of-Life Assessment, X-Ray Imaging
Radiation · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
678
States / cities
Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Not applicable Interventional Results available

Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria

NCT01481935
View directory record Official record
Conditions
Infection Control
Interventions
Enhanced cleaning of surfaces in ICU rooms, Sham enhanced cleaning of surfaces in ICU rooms
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Transversus Abdominis Plane Block

NCT06274307
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Transversus abdominis plane block
Procedure
Lead sponsor
Justin Hruska
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 10, 2026, 1:07 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

NCT00850993
View directory record Official record
Conditions
Hyperbilirubinemia, Neonatal
Interventions
Stannsoporfin, Placebo, PhotoTherapy (as needed)
Drug · Other
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
1 Minute to 48 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Colton, California • San Diego, California • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 10, 2026, 1:07 PM EDT
Recruiting Not applicable Interventional

Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients

NCT03245411
View directory record Official record
Conditions
Cancer
Interventions
Intervention
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 10, 2026, 1:07 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers

NCT02838784
View directory record Official record
Conditions
Venous Ulcer, Foot Ulcer, Diabetic
Interventions
Artacent Human Amniotic Membrane, Standard of Care
Other · Procedure
Lead sponsor
Tides Medical
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
7
States / cities
Arcadia, California • New Iberia, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 10, 2026, 1:07 PM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 10, 2026, 1:07 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain

NCT05575999
View directory record Official record
Conditions
Pain Management
Interventions
Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination
Drug
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Loma Linda, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 10, 2026, 1:07 PM EDT
Completed Not applicable Interventional

Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings

NCT03711292
View directory record Official record
Conditions
Antimicrobial Stewardship, Acute Bronchitis, Upper Respiratory Infection
Interventions
Antibiotic Stewardship
Behavioral
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
21 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 10, 2026, 1:07 PM EDT
Terminated Phase 2 Interventional Results available

Tivozanib As Maintenance Therapy In GYN

NCT01972516
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Tivozanib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 10, 2026, 1:07 PM EDT
Recruiting No phase listed Observational

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

NCT04913311
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Biospecimen Collection, Bronchoscopy with Bronchoalveolar Lavage, Chemoradiotherapy, Computed Tomography, Diagnostic Laboratory Biomarker Analysis, Immune Checkpoint Inhibitor, Nasal Wash and Collection, Quality-of-Life Assessment, Questionnaire Administration, Spirometry
Procedure · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 1:07 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

NCT04614766
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions
Lutathera, Azedra
Drug
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 10, 2026, 1:07 PM EDT
Recruiting Phase 4 Interventional

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

NCT06218199
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Furosemide, Torsemide, Bumetanide, sacubitril/valsartan, Hydralazine, Isosorbide Dinitrate
Drug
Lead sponsor
Heart Center Research, LLC
Network
Eligibility
19 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 10, 2026, 1:07 PM EDT